ESR1 and breast cancer: Besides their antiproliferative activity, palbociclib has shown strong antimetastatic activity in a dose-dependent manner through reducing cyclooxygenase-II expression in MDA-MB-231 (ERα−) and T47D (ERα+) breast cancer cells [13].